For immediate release. Vancouver, British Columbia, April 22, 2024: Cannabix Technologies Inc.(CSE: BLO, OTC PINK CURRENT: BLOZF)  (Frankfurt: 8CT) (the “Company”)  developer of marijuana breathalyzer devices for law enforcement and the workplace reports that it will be presenting at the International Association for Chemical Testing (IACT) conference in April.  Cannabix’s Dr. Bruce Goldberger Ph.D., will be presenting on Science & Technology Behind Cannabis Breath Testing and the Company’s marijuana breathalyzer system at the conference workshop session. IACT is composed of governmental agency personnel involved in chemical testing related to traffic safety. IACT members are scientific and criminal justice professionals, including forensic scientists, regulatory inspectors, and law enforcement personnel with representatives from a majority of states and international members. IACT has standing committees to address various areas including legislation, training, new equipment and procedures and manufacturers of breath testing equipment.

The Cannabis Breath Testing workshop at IACT 2024 is designed to provide background information regarding the pharmacokinetics and pharmacodynamics of cannabinoids in breath, present the current technology for collection devices from commercial vendors, and discuss the necessary laboratory workflows and analytical considerations when testing these samples.

Dr. Bruce Goldberger is a professor and the former Chief of the Forensic Medicine Division in the Department of Pathology, Immunology and Laboratory Medicine in the College of Medicine at the University of Florida. Dr. Goldberger served as Director of the University of Florida forensic toxicology laboratory for 30 years. Dr. Goldberger is the Principal Investigator of the Florida Drug-Related Outcomes  Surveillance and Tracking System and Co-investigator of the National Drug Early Warning System. Dr. Goldberger is a consultant for the Centers for Disease Control and Prevention’s National Center for Injury Prevention and Control, Overdose Mortality Team, and the National Center for Health Statistics, Division of Vital Statistics. Dr. Goldberger is a consultant and senior advisor to Cannabix Technologies Inc.

About Cannabix Technologies Inc.
Cannabix Technologies Inc. is a developer of marijuana and alcohol breathalyzer technologies for law enforcement, workplaces and laboratories. Cannabix is developing delta-9 THC and alcohol screening devices. Delta-9 THC is the psychoactive component of marijuana that causes impairment. Breath testing for delta-9 THC would allow employers and law enforcement to identify recent marijuana use. Cannabix is the developer of Breath Logix Series of autonomous breath alcohol detection devices for employers and a range of other settings.

We seek Safe Harbor.

On behalf of the Board of Directors

“Rav Mlait”

CEO
Cannabix Technologies Inc.

For further information, contact us by visiting https://cannabixtechnologies.com/contact/contact-us/ 

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking information that involves various risks and uncertainties regarding future events. Such forward-looking information can include without limitation statements based on current expectations involving a number of risks and uncertainties and are not guarantees of future performance of the Company, such as final development of a commercial or prototype product(s), successful trial or pilot of company technologies, no assurance that commercial sales of any kind actually materialize; no assurance the Company will have sufficient funds to complete product development. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information, including: (i) adverse market conditions; (ii) risks regarding protection of proprietary technology; (iii) the ability of the Company to complete financings; (iv) the ability of the Company to develop and market its future product; and (v) risks regarding government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company’s public announcements and filings. There is no assurance that its development of breathalyzer technologies will provide any benefit to the Company, and no assurance that any proposed new products will be built, will be successful in beta testing or clinical trials. The is no assurance that the Company will enter into any partnerships to advance any of its corporate initiatives or technologies. There is no assurance that any “patent pending” or “provisional patents” technologies licensed by the Company or owned by the Company will receive patent status by regulatory authorities.  The Company is not currently selling commercial breathalyzers. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.

Neither CSE nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

Contact
For additional information on Cannabix Technologies Inc. please visit our website at https://cannabixtechnologies.com/contact/contact-us/ 

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

With cannabis legalization sweeping across North America after decades of prohibition, there are some natural concerns surrounding the introduction of the drug to the legal marketplace. In the area of safety, most of the questions have surrounded the issue of impaired driving. One topic that hasn’t gotten a lot of press is that of workplace safety. The most widely-used, current workplace testing solution involves urinalysis, a cumbersome process that is often applied to screen applicants but is not necessarily practical for the detection of recent use on a regular basis.

Cannabix Technologies Inc. (CSE: BLO) (OTC: BLOZF) is actively developing the Cannabix Marijuana Breathalyzer, designed for roadside use by law enforcement officials. The company recently announced the licensing of patent-pending technology, developed by researchers at the University of British Columbia (UBC), that will be focused to offer a cannabis testing solution for workplace and even parental use. Recognizing that the requirements of potential end users vary greatly, Cannabix is looking to offer flexible solutions to meet the needs of a variety of markets.

Workplace Safety and Cannabis

In general, there is still much to be learned from scientific research into cannabis. This is an unsurprising side effect of nearly a century of cannabis prohibition, which greatly limited research on the plant. However, there is growing research that points to workplace issues surrounding cannabis.

A study of postal workers from 1992 showed that employees who tested positive for marijuana in pre-employment screening had significantly more accidents, injuries, and absenteeism compared with those who tested negative. Another study from 2010 pointed to the shortcomings of relying on pre-employment drug screening as a tool to improve workplace safety. Major conclusions included the fact that recent cannabis use (within 4 hours) led to impairment, something that urinalysis screening would not catch. Additionally, urinalysis was not shown to have a meaningful impact on job accident rates.

Parents have their own set of concerns. A 2008 study found that heavy adolescent use of marijuana negatively impacts attention, memory, and learning. A longitudinal study published in 2004 showed a correlation between cannabis use and lower educational attainment. As we have seen with the recent college admissions scandal, there are definitely pressures to do whatever it takes to help children succeed. Being able to conveniently test for marijuana use probably lies at the least invasive, ethically clean end of the spectrum of potential parental actions.

Marijuana Breathalyzer technologies

Cannabix Technologies recognizes the varying needs of the wide range of its potential clients as it develops reliable and portable cannabis testing units. As a first step, the company knows that everyone would prefer a test that doesn’t have to be sent to a lab to analyze results. The breathalyzer model is universally preferred as well, when compared to tests that require the collection of bodily fluids. From that basis, needs start to diverge.

Roadside breathalyzers need to work in all manner of environmental conditions, be rugged and accurate, returning results that will eventually hold up in court. Workplace and parental users will usually be operating in much more controlled environments, and the scrutiny of the results will usually not rise to the level of court proceedings. There is price sensitivity between the markets as well. Employers want to know if someone can safely do their job, and parents want to know if their child has been smoking marijuana before getting behind the wheel of the family car.

Cannabix’s THC Breath Analyzer.

The Cannabix Marijuana Breathalyzer uses field asymmetric waveform ion mobility spectrometry (FAIMS) technology to detect THC from breath samples. FAIMS is an analytical chemistry technology that filters and identifies substances by separating ions. It has the ability to connect directly with Mass Spectrometry technology to confirm its highly sensitive roadside results in the lab, improving the chance that the results stand up in the courts. The THC Breath Analyzer utilizes lower-cost yet highly-effective, versatile, microfluidic sensors that can provide results quickly and cost efficiently.

The Upshot

As with any product company, Cannabix is analyzing the needs of its potential target markets and developing products with features to match those markets. The recent licensing announcement greatly expands the company’s potential client base, and the company expects the resulting THC Breath Analyzer to be available for expanded testing soon, so keep an eye out for further developments as Cannabix Technologies does its part to solve some of the public safety concerns surrounding cannabis use behind the wheel, on the job, and amongst adolescents.

About CFN Media

For Visitors and Viewers 

CFN Media’s Cannabis Financial Network (CannabisFN.com) is the destination for savvy investors and business people profiting from the worldwide cannabis industry. Viewers will see breaking news, exclusive content and original programming involving the people, companies and investments shaping the industry.

For Cannabis Businesses & Companies 

CFN Media is a leading agency and financial media network dedicated to the cannabis industry. We help private, pre-public and public cannabis companies in the US and Canada attract capital, investors and media attention.

Our powerful digital media and distribution platform conveys a company’s message and value proposition directly to accredited and retail investors and national media active in the North American cannabis markets.

Since 2013, CFN Media has enabled the world’s preeminent cannabis companies to thrive in the capital and public markets.

About Robin Lefferts